Da Costa Lydie, Narla Anupama, Mohandas Narla
Université Paris 7 Denis Diderot-Sorbonne, Paris, France.
AP-HP, Hematology laboratory, Robert Debré Hospital, Paris, France.
F1000Res. 2018 Aug 29;7. doi: 10.12688/f1000research.15542.1. eCollection 2018.
Diamond-Blackfan anemia (DBA) is a rare congenital hypoplastic anemia characterized by a block in erythropoiesis at the progenitor stage, although the exact stage at which this occurs remains to be fully defined. DBA presents primarily during infancy with macrocytic anemia and reticulocytopenia with 50% of cases associated with a variety of congenital malformations. DBA is most frequently due to a sporadic mutation (55%) in genes encoding several different ribosomal proteins, although there are many cases where there is a family history of the disease with varying phenotypes. The erythroid tropism of the disease is still a matter of debate for a disease related to a defect in global ribosome biogenesis. Assessment of biological features in conjunction with genetic testing has increased the accuracy of the diagnosis of DBA. However, in certain cases, it continues to be difficult to firmly establish a diagnosis. This review will focus on the diagnosis of DBA along with a description of new advances in our understanding of the pathophysiology and treatment recommendations for DBA.
钻石黑范贫血(DBA)是一种罕见的先天性再生障碍性贫血,其特征是在祖细胞阶段红细胞生成受阻,尽管确切发生阶段仍有待完全明确。DBA主要在婴儿期出现,表现为大细胞性贫血和网织红细胞减少,50%的病例伴有各种先天性畸形。DBA最常见的原因是编码几种不同核糖体蛋白的基因发生散发性突变(55%),尽管有许多病例有该病家族史且表型各异。对于一种与整体核糖体生物发生缺陷相关的疾病,其红系嗜性仍存在争议。结合基因检测评估生物学特征提高了DBA诊断的准确性。然而,在某些情况下,仍难以明确诊断。本综述将重点关注DBA的诊断,同时描述我们对其病理生理学理解的新进展以及DBA的治疗建议。